SuperworthImmuneering revenue IMRX
Sales by quarter and over the last twelve months, from 2020.
- Last 12 months, to Dec 31, 2023
- $0
- Latest quarter, Q4 FY23
- $0
- −100% on a year earlier
- Fiscal year 2023
- $0
- −100% on the year before
Immuneering's revenue was $0 over the twelve months to Dec 31, 2023, down 100% on a year earlier.
In its latest quarter, Q4 FY23, it was $0, down 100% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2023 | $0 | −100% |
| FY2022 | $317K | −85% |
| FY2021 | $2.1M | −10% |
| FY2020 | $2.3M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY23 | $0 | −100% | $0 | |
| Q3 FY23 | $0 | −100% | $455 | |
| Q2 FY23 | $0 | −100% | $38.8K | |
| Q1 FY23 | $0 | −100% | $133.3K | |
| Q4 FY22 | $455 | −100% | $317K | |
| Q3 FY22 | $38.4K | −92% | $506.1K | |
| Q2 FY22 | $94.4K | −86% | $949.8K | |
| Q1 FY22 | $183.7K | −75% | $1.5M | |
| Q4 FY21 | $189.6K | −71% | $2.1M | |
| Q3 FY21 | $482.1K | −29% | $2.6M | |
| Q2 FY21 | $660K | +37% | $2.8M | |
| Q1 FY21 | $748.2K | +55% | $2.6M |
Against its peers
Companies in Drug Manufacturers - General nearest Immuneering's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| IMRXImmuneering | n/m | |
| NATRNatures Sunshine Products | $492M | +7% a year |
| ARVNArvinas | $316.7M | −15% a year |
| PBYIPuma Biotechnology | $231.2M | −3% a year |
| IRWDIronwood Pharmaceuticals | $389.3M | +26% a year |
| ZVRAZevra Therapeutics | $136.1M | +119% a year |
| CRMDCorMedix | $462.2M | +281% a year |
| COLLCollegium Pharmaceutical | $808.2M | +14% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| ABUSArbutus Biopharma | $181.7M | |
| SPROSpero Therapeutics | $47M | −3% a year |
| Peer median | $274M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Immuneering
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.